New York, NY(July 27, 2023)-Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.
2023
Merck and Moderna announce Phase III V940 trial for melanoma patients
Merck (MSD) and Moderna are initiating a Phase III trial evaluating V940, an investigational individualised neoantigen therapy (INT), in combination with Keytruda, to treat patients with resected high-risk (Stage IIB-IV) melanoma.
Phase 3 Trial Underway for Novel Pembrolizumab Combination for Treatment of High-Risk Melanoma
Pembrolizumab is already indicated to treat patients with unresectable or metastatic melanoma, along with stage 2B-3 melanoma after resection in adults and pediatric patients.
Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma
Newswise — Immune-checkpoint inhibitors have become the standard of care for patients with advanced melanoma to improve survival, but only some patients respond to this immunotherapy and have long-term benefits.